Predictive Oncology

Predictive Oncology leverages artificial intelligence/machine learning integrated with a large biobank of over 150,000 tumor samples to predict drug responses with high accuracy (~92% in proof-of-concept studies). Its platforms support pharmaceutical partners’ preclinical oncology programs by optimizing candidate selection based on real-world tumor heterogeneity. The company’s subsidiaries provide specialized CRO services including advanced cell culture models, protein/peptide formulation technologies, GMP manufacturing capabilities for research reagents/media/proteins, and automated fluid management systems. Recent partnerships include Cancer Research UK to accelerate oncology drug development using the PEDAL platform.